ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) GREENHOUSE GAS EMISSIONS Neuren’s small workforce all work from home and no office or other facility is maintained. Neuren engaged a third-party to confirm Neuren’s Scope 1 and 2 operational emissions for the year ended 31 December 2025. The emission boundary has been defined based on the operational control approach. Scope 1 emissions are direct greenhouse gas (GHG) emissions emitted from sources that are owned or controlled by the disclosing organisation, for example, emissions from combustion in owned or controlled boilers, furnaces, vehicles, or emissions from chemical production in owned or controlled process equipment. Scope 2 emissions are GHG emissions from the generation of purchased electricity consumed by the organisation. For the year ended 31 December 2025, Neuren had zero Scope 1 and 2 emissions, calculated in accordance with The Greenhouse Gas Protocol – A Corporate Accounting and Reporting Standard, World Resources Institute/World Business Council for Sustainable Development (the GHG Protocol). The Company’s Scope 1 and 2 emissions assessment was independently reviewed, and it was determined that the Group had no Scope 1 or 2 emissions for the reporting period. This was due to the Company not operating or controlling any physical offices, facilities or directly owned assets during the reporting period. SOCIAL IMPACT Neuren’s work to develop treatments for serious neurodevelopmental disorders that have no approved medicines and have a devastating impact on families potentially has a very high positive social impact, which is also highly motivating for Neuren’s workforce. Throughout its development programs, Neuren works closely with the patient communities for each of the disorders and provides financial support to events organised by patient advocacy organisations. Neuren’s policy of full time working from home provides people with high flexibility and enables optimum work/ life balance. It also enables Neuren to engage highly skilled people wherever they are located. The small size of the team and relatively flat structure facilitates opportunities to experience and take responsibility for a broader range of activities than would typically be available in larger companies. DAYBUE, which is licensed by Neuren to Acadia Pharmaceuticals, is the only product in the world approved to treat Rett syndrome. It is widely available to Rett syndrome patients in the United States, at nominal cost to families through coverage by health insurance and government programs. It is also available under named patient supply programs across multiple regions including Europe, the Middle East and Latin America. Acadia is pursuing a Marketing Authorization Application (MAA) in Europe and conducting a clinical trial to support a marketing application in Japan. Neuren’s second product NNZ-2591 has the potential to be the first ever treatment for children with Phelan-McDermid and Pitt Hopkins syndromes. Neuren conducts human clinical trials of its potential treatments through registration with regulators such as the US Food and Drug Administration (FDA). The standards required by the regulators include adherence to ICH Good Clinical Practice ethical and quality standards, prior approval by independent ethics committees and prior written consent by participants, who are fully informed of risks, benefits, and procedures. Studies in animals are currently required by regulators around the world to support approval of new medicines. Where required, animal studies may play an important role in reducing safety risks before the drug is administered in vulnerable patient populations. Neuren commissions animal research where it is necessary to meet regulatory requirements or advance development in one of the rare pediatric indications being pursued. Neuren supports the 3R principles of animal research; replacement of animals, reduction in the number of animals used and refinement of conditions and methodology to reduce suffering. Studies are conducted only by reputable third parties that adhere to the highest ethical and scientific standards, maintain AALAC International accreditation and have demonstrated adherence to recognised international animal welfare standards. Where scientifically feasible and acceptable to regulators, Neuren prioritises non-animal study approaches. During the year, Neuren funded the development of human cell models that mimic neurons with genetic mutations as an alternative to animal models for assessment of drug effects. CORPORATE GOVERNANCE STATEMENT Neuren’s board of directors (“Board”) aims to ensure that the Company and its subsidiaries (the “Group”) operates with a corporate governance framework and practices that promote an appropriate governance culture throughout the organisation and that are relevant, practical and costeffective for the current size and stage of development of the business. This Statement is current as at 31 March 2026 and has been approved by the Board of Neuren Pharmaceuticals Limited. This Statement provides a description of the framework and practices, laid out under the structure of the ASX Listing Rules and the Corporate Governance Principles (the “Principles”) and Recommendations (the “Recommendations”) 4th Edition. Neuren Pharmaceuticals Limited Annual Report 2025 24
RkJQdWJsaXNoZXIy MjE2NDg3